Sequence variability in p6 gag protein and gag/pol coevolution in human immunodeficiency type 1 subtype f genomes

AIDS Research and Human Retroviruses

Volumn 29, Issue 7, 2013, Pages 1056-1060

  Rossi, Andres H ^a   Rocco, Carlos A ^a   Mangano, Andrea ^a   Sen, Luisa ^a   Aulicino, Paula C ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; NELFINAVIR;

ARTICLE; COEVOLUTION; DRUG SENSITIVITY; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; INDEL MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRAL GENETICS; VIRUS GENOME; VIRUS MUTATION; VIRUS RESISTANCE;

AMINO ACID SEQUENCE; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENES, GAG; GENES, POL; GENETIC VARIATION; GENOME, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NELFINAVIR;

EID: 84879147184     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0311     Document Type: Article

References (21)

1. Hemelaar J, Gouws E, Ghys PD, and Osmanov S: Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011;25(5):679-689.
2. Carr JK, Avila M, and Gomez Carrillo M, et al.: Diverse BF recombinants have spread widely since the introduction of HIV-1 into South America. AIDS 2001;15:F41-F47.
3. Quarleri JF, Rubio A, Carobene M, et al.: HIV type 1 BF recombinant strains exhibit different pol gene mosaic patterns: Descriptive analysis from 284 patients under treatment failure. AIDS Res Hum Retroviruses 2004;20: 1100-1107.
4. Dilernia DA, Gomez AM, Lourtau L, et al.: HIV type 1 genetic diversity surveillance among newly diagnosed individuals from 2003 to 2005 in Buenos Aires, Argentina. AIDS Res Hum Retroviruses 2007;23:1201-1207.
5. Aulicino PC, Bello G, Guimaraes ML, et al.: Longitudinal analysis of HIV-1 BF1 recombinant strains in vertically infected children from Argentina reveals a decrease in CRF12 BF pol gene mosaic patterns and high diversity of BF unique recombinant forms. Infect Genet Evol 2011;11(2): 349-357.
6. Martinez-Cajas JL, Pai MP, Klein MB, and Wainberg MA: Differences in resistance mutations among HIV-1 nonsubtype B infections: A systematic review of evidence (1996-2008). J Int AIDS Soc 2009;30:12-11.
7. Rhee SY, Kantor R, Katzenstein DA, et al.: HIV-1 pol mutation frequency by subtype and treatment experience: Extension of the HIVseq program to seven non-B subtypes. AIDS 2006;20:643-651.
8. Aulicino PC, Rocco CA, Mecikovsky D, Bologna R, Mangano A, and Sen L: HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N + L100I and L74V mutations. Antivir Ther 2010;15(4):641-650.
9. Ganser-Pornillos BK, Yeager M, and Sundquist WI: The structural biology of HIV assembly. Curr Opin Struct Biol 2008;18(2):203-217.
10. Bally F, Martinez R, Peters S, Sudre P, and Telenti A: Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: Clinical significance and implications for resistance to protease inhibitors. AIDS Res Hum Retroviruses 2000; 16(13):1209-1213.
11. Marlowe N, Flys T, Hackett J Jr, et al.: Analysis of insertions and deletions in the gag p6 region of diverse HIV type 1 strains. AIDS Res Hum Retroviruses 2004;20(10):1119-1125.
12. Holguín A, Alvarez A, and Soriano V: Differences in the length of gag proteins among different HIV Type 1 subtypes. AIDS Res Hum Retroviruses 2005;21:886-893.
13. Martins AN, Arruda MB, Pires AF, Tanuri A, and Brindeiro RM: Accumulation of P(T/S)AP late domain duplications in HIV Type 1 subtypes B, C, and F derived from individuals failing ARV therapy and ARV drug-näve patients. AIDS Res Hum Retroviruses 2011;27(6):687-692.
14. Peters S, Muñ oz M, Yerly S, et al.: Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. J Virol 2001;75: 9644-8653.
15. Schneider TD and Stephens RM: Sequence logos: A new way to display consensus sequences. Nucleic Acids Res 1990; 18:6097-6100.
16. Crooks GE, Hon G, Chandonia JM, and Brenner SE: Web-Logo: A sequence logo generator. Genome Res 2004;14: 1188-1190.
17. Vacic V, Iakoucheva LM, and Radivojac P: Two Sample Logo: A graphical representation of the differences between two sets of sequence alignments. Bioinformatics 2006;22: 1536-1537.
18. Ojesina A, Chaplin B, Sankalé J-L, et al.: Interplay of reverse transcriptase inhibitor therapy and Gag p6 diversity in HIV Type 1 subtype G and CRF02 AG. AIDS Res Hum Retroviruses 2008;24(9):1167-1174.
19. Lastere S, Dalban C, Collin G, et al.: Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir. Antiviral Ther 2004;9:221-227.
20. Verheyen J, Litau E, Sing T,et al.: Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapynaive and therapy-experienced patients. Antiviral Ther 2006; 11(7):879-887.
21. Shibata J, Sugiura W, Ode H, et al.: Within-host co-evolution of gag P453L and protease D30N/N88D demonstrates virological advantage in a highly protease inhibitor-exposed HIV-1 case. Antiviral Res 2011;90(1):33-41.